Syncona Limited

Publication of 2021 Annual Report and Notice of Annual General Meeting

1 July 2021

Syncona Limited ("Syncona") today announces that it has published its Annual Report and Accounts for the year ended 31 March 2021 ("2021 Annual Report") and its Notice of Annual General Meeting 2021.

In compliance with Listing Rule 9.6.1, these documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

Copies of these documents, together with the Form of Proxy for use in connection with the 2021 Annual General Meeting are available on Syncona's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/. Printed copies of these documents are also being posted to shareholders where requested.

Syncona's Annual General Meeting will be held at 10:30am on 3 August 2021 at the offices of Citco Fund Services (Guernsey) Limited, Arnold House, St Julian's Avenue, St. Peter Port, Guernsey, GY1 3RD. Given the ongoing restrictions from the COVID-19 global pandemic, shareholders are strongly encouraged to ensure that their votes are counted at the 2021 Annual General Meeting by appointing the chair of the 2021 Annual General Meeting as their proxy in line with the procedures set out in the Notice of Annual General Meeting.

Enquiries

Syncona Limited
Annabel Clay
Tel: +44 (0) 20 3981 7940

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.